Hypofractionated radiotherapy for 45 cancer patients with hepatic metastasis
10.3760/cma.j.issn.1004-4221.2018.11.006
- VernacularTitle:体部大分割放射治疗肝转移癌疗效及安全性
- Author:
Ruizhi ZHAO
1
;
Jianping XIAO
;
Hongmei ZHANG
;
Yuchao MA
;
Siran YANG
;
Qingfeng LIU
;
Ye ZHANG
;
Kai WANG
;
Lei DENG
;
Nan BI
;
Wenqing WANG
;
Junlin YI
;
Yexiong LI
Author Information
1. 国家癌症中心/中国医学科学院北京协和医学院肿瘤医院放疗科
- Keywords:
Hepatic metastatic neoplasm/hypofractionated radiotherapy;
Therapeutic outcome
- From:
Chinese Journal of Radiation Oncology
2018;27(12):1061-1065
- CountryChina
- Language:Chinese
-
Abstract:
Objectives To evaluate the clinical efficacy and safety of hypofractionated radiotherapy for cancer patients with hepatic metastases. Methods From May 2007 to November 2016,45 patients ( male:female=20:25) with inoperable hepatic metastases were enrolled in this investigation. The median age was 58 years old ( range:25-83).The median Karnofsky performance score ( KPS) was 80.Primary colorectal cancer was detected in 14 patients,primary breast cancer in 9 and primary lung cancer in 6 cases. Twenty-one patients had extrahepatic metastases. A total of 52 lesions were treated. Thirty-four cases received radiotherapy for one single lesion. The fractional dose was 45 Gy/3 fractions and 60 Gy/10-15 fractions. The median gross tumor volume (GTV) was 10. 1 cm3(0. 3-175. 2 cm3) and 29. 8 cm3(5. 0-209. 6 cm3) for planning target volume ( PTV).Seventeen CT images were fused with MRI and IMRT was adopted in 43 cases. The median dose of PTV was 60 Gy (40-60 Gy) and 90 Gy (60-132 Gy) for bioequivalent dose (BED). Results The median follow-up time was 23. 5 months and the median survival time was 26. 0 months (95%CI:21.4-30.6 months).The 1-year local control (LC),disease-free survival (DFS) and overall survival ( OS ) were 94%, 27% and 91%, respectively. Six cases died of liver metastases and abnormal liver function. Conclusion Hypofractionated radiotherapy is an efficacious and safe local treatment for inoperable hepatic metastases.
